How Much Does Vyleesi Cost in Louisiana in 2026?

Brand-Name Vyleesi Pricing at Louisiana Pharmacies

The manufacturer list price for Vyleesi sits at $1,200 per month in 2026, and Louisiana retail pharmacies generally charge that full amount to cash-pay patients. This price covers a supply of single-use, prefilled auto-injectors containing 1.75 mg of bremelanotide each 1.

Prices can vary by $50 to $100 depending on the pharmacy. Large chains in Baton Rouge, New Orleans, and Shreveport tend to cluster near $1,200, while independent pharmacies occasionally price slightly lower or higher. Requesting a price quote by phone before filling a prescription is a practical step that takes five minutes.

The FDA approved bremelanotide in June 2019 for premenopausal women with acquired, generalized HSDD 1. Approval rested on the RECONNECT trials, two Phase 3, randomized, double-blind studies (combined N=1,247) that showed bremelanotide significantly increased sexual desire and decreased distress compared to placebo over 24 weeks 2. In RECONNECT, the mean change from baseline in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13 score was -1.7 for bremelanotide versus -1.0 for placebo (P<0.001) 2. These are the numbers that underpin the $1,200 price tag: a drug with demonstrated efficacy, but limited competition.

Louisiana Medicaid and Vyleesi: No Coverage

Louisiana Medicaid does not cover Vyleesi as of May 2026. The drug is excluded from the state's preferred drug list, and no prior authorization pathway currently exists to obtain it through Medicaid fee-for-service or any of Louisiana's Medicaid managed care organizations.

This exclusion is not unique to Louisiana. Most state Medicaid programs classify bremelanotide as a "lifestyle" medication, placing it alongside drugs for erectile dysfunction in formulary exclusion tiers. The Endocrine Society has noted that HSDD is a recognized medical condition with measurable diagnostic criteria, distinct from normal fluctuations in desire 3. That clinical framing has not yet changed Louisiana Medicaid policy.

Women enrolled in Louisiana Medicaid who want bremelanotide have two realistic alternatives: pay out-of-pocket at the brand-name or compounded price, or explore manufacturer discount programs. The Palatin Technologies savings card (discussed below) may provide some relief, though it requires a valid prescription and is not stackable with any government insurance program, including Medicaid, Medicare, or TRICARE.

Private Insurance Coverage in Louisiana

Private insurance coverage for Vyleesi in Louisiana ranges from nonexistent to heavily restricted. Blue Cross Blue Shield of Louisiana, Humana, UnitedHealthcare, and Aetna plans sold in the state may cover bremelanotide under specialty pharmacy tiers, but nearly all require prior authorization and step therapy documentation 1.

Typical prior authorization criteria include:

• A formal HSDD diagnosis using validated screening tools
• Documentation that the condition is acquired and generalized (not situational)
• Confirmation the patient is premenopausal
• Evidence that non-pharmacologic interventions (counseling, relationship therapy) were attempted or considered
• Verification that the patient is not using the drug for an off-label purpose

Even when approved, copays on specialty tiers can reach $200 to $400 per month. That is why many Louisiana patients with private insurance still end up comparing the out-of-pocket cost against the compounded alternative.

Dr. Sheryl Kingsberg, a clinical psychologist and HSDD researcher involved in the RECONNECT trials, stated in a 2019 interview: "The biggest barrier to treatment for HSDD is not the science. It is access. Women are told their condition isn't real, or their insurance won't cover the treatment" 2.

Contact your insurer's pharmacy benefits line directly and ask two specific questions: (1) Is bremelanotide on formulary? (2) What tier is it on, and what is the estimated copay? These two data points tell you whether insurance is worth pursuing or whether the compounded route is cheaper.

Compounded Bremelanotide in Louisiana: Legal, Accessible, and Cheaper

Compounded bremelanotide is available in Louisiana through licensed 503A compounding pharmacies. The price averages approximately $140 per month, roughly 88% less than the brand-name product 4.

A 503A pharmacy operates under Section 503A of the Federal Food, Drug, and Cosmetic Act. It compounds medications based on individual patient prescriptions from a licensed prescriber 4. Louisiana's Board of Pharmacy regulates these facilities under state law, and bremelanotide is not on the FDA's "difficult to compound" or "demonstrably difficult" lists, which means 503A pharmacies can legally prepare it.

Key differences between brand-name Vyleesi and compounded bremelanotide:

Delivery method. Brand-name Vyleesi comes in a single-use auto-injector. Compounded bremelanotide is typically dispensed as a multi-dose vial with syringes, or as pre-filled syringes.

Bioequivalence testing. Compounded formulations do not undergo the same FDA bioequivalence review as brand-name drugs. The active ingredient is the same molecule (bremelanotide acetate), but excipients, concentration accuracy, and sterility standards depend on the compounding pharmacy's quality controls.

Cost. At $140 versus $1,200, compounded bremelanotide costs approximately $1,060 less per month. Over a year, that is a difference of roughly $12,720.

To obtain compounded bremelanotide in Louisiana, a prescriber must write a prescription specifying the drug, dose (typically 1.75 mg per injection), and route (subcutaneous). The prescription goes to a licensed 503A compounding pharmacy. Several Louisiana-based compounding pharmacies fill bremelanotide prescriptions, and out-of-state 503A pharmacies can also ship to Louisiana patients, provided they hold the required state licenses.

Telehealth Prescribing: How to Get Vyleesi Without an In-Person Visit

Louisiana permits telehealth prescribing of Vyleesi and compounded bremelanotide. A prescriber licensed in Louisiana can evaluate a patient via synchronous video visit, diagnose HSDD, and write the prescription electronically 5.

This is significant for women in rural Louisiana parishes. The state has 64 parishes, and many lack a local sexual medicine specialist. Telehealth removes the geographic barrier. A patient in Lake Charles, Houma, or Monroe can see a prescriber based in New Orleans or Baton Rouge (or another state, if that prescriber holds a Louisiana license) without driving hours each way.

The telehealth workflow typically follows this sequence:

1. Schedule a video consultation with a prescriber who treats HSDD
2. Complete intake forms, including medical history and a validated HSDD screening questionnaire
3. Discuss symptoms, duration, distress level, and prior treatments during the visit
4. Receive a prescription sent electronically to a retail or compounding pharmacy
5. Pick up or receive the medication by mail

Louisiana does not require an initial in-person visit before a telehealth prescription for bremelanotide. The prescriber must, however, establish a legitimate provider-patient relationship during the video visit. A phone-only consultation without video is generally not sufficient for a new patient encounter under current Louisiana telemedicine regulations.

The Palatin Technologies Savings Card

Palatin Technologies, the manufacturer of Vyleesi, offers a patient savings card that reduces out-of-pocket costs for commercially insured patients. The program is available to Louisiana residents who meet eligibility criteria 1.

Standard terms for the savings card:

• Available to patients with commercial (private) insurance only
• Not valid for patients covered by Medicare, Medicaid, TRICARE, or any other government-funded program
• Copay reduction up to a specified annual maximum (terms vary by program year; check the current card for 2026 limits)
• The card is presented at the pharmacy along with the insurance card at time of fill

For uninsured Louisiana patients, Palatin has periodically offered a separate cash-pay discount, though availability and terms change. Calling the number on the Palatin patient support website or asking your prescriber's office to check current programs is the most reliable approach.

The savings card does not apply to compounded bremelanotide. It is valid only for the brand-name Vyleesi auto-injector dispensed through a retail or specialty pharmacy.

Comparing All Louisiana Pricing Options

Here is a side-by-side breakdown for a Louisiana patient filling one month of bremelanotide in 2026:

Brand-name Vyleesi, no insurance: $1,200. This is the cash price at most Louisiana retail and specialty pharmacies.

Brand-name Vyleesi, commercial insurance with prior auth approved: $50 to $400, depending on tier and plan design. A savings card may reduce this further.

Brand-name Vyleesi, Medicaid: not covered. Full cash price applies if obtained.

Compounded bremelanotide, 503A pharmacy: approximately $140. No insurance billing; paid out of pocket directly to the compounding pharmacy.

For a patient using bremelanotide twice per month (the median frequency in the RECONNECT trials was 1.6 uses per month 2), the annual cost comparison looks like this:

• Brand-name, no insurance: $14,400 per year
• Compounded, 503A: approximately $1,680 per year
• Brand-name with savings card (estimated): $3,600 to $7,200 per year, depending on copay and card terms

The compounded route is the least expensive option for most Louisiana patients who lack strong insurance coverage.

Safety Considerations That Affect Cost Decisions

Cost should not be the only factor. The FDA labeling for Vyleesi carries specific safety warnings that every patient should review with her prescriber before starting treatment 1.

Blood pressure. Bremelanotide causes a transient increase in systolic blood pressure of approximately 6 mmHg, peaking about 2 to 3 hours post-injection. Women with uncontrolled hypertension or significant cardiovascular disease should not use it 1.

Nausea. In the RECONNECT trials, 40.0% of bremelanotide-treated patients reported nausea versus 1.3% on placebo 2. Nausea was the most common reason for discontinuation. It tends to diminish with repeated dosing, but the first few uses are often the worst.

Skin hyperpigmentation. Bremelanotide is a melanocortin receptor agonist. About 1% of patients in clinical trials developed focal hyperpigmentation (darkened patches of skin on the face, gingiva, or breasts) that did not fully resolve after stopping the drug 1.

Dosing limit. The label specifies no more than one dose per 24 hours and no more than 8 doses per month 1.

These safety parameters are identical whether you use brand-name Vyleesi or compounded bremelanotide. The molecule is the same. The risks are the same. What differs is the delivery device, the price, and the level of manufacturing oversight.

Steps to Get the Lowest Price in Louisiana

A practical sequence for a Louisiana patient seeking the most affordable bremelanotide access:

1. Check insurance first. Call your pharmacy benefits line. Ask if bremelanotide/Vyleesi is on formulary, what tier, and what the estimated copay is after prior authorization.
2. Request prior authorization if covered. Your prescriber's office submits clinical documentation. Expect 5 to 15 business days for a decision.
3. Apply the savings card if commercially insured. This stacks on top of your insurance copay and may bring the cost below $100 per month.
4. If uninsured or underinsured, go compounded. Ask your prescriber to write the prescription for compounded bremelanotide 1.75 mg subcutaneous and send it to a licensed 503A pharmacy. Confirm the pharmacy holds a current Louisiana Board of Pharmacy compounding license.
5. Use telehealth if access is a barrier. A video visit with a licensed Louisiana prescriber can generate the prescription without requiring travel.

The ISSWSH (International Society for the Study of Women's Sexual Health) clinical practice guidelines recommend that treatment of HSDD should include both pharmacologic and non-pharmacologic components, noting: "Pharmacologic therapy should be offered when distress is clinically significant and non-pharmacologic options alone are insufficient" 6.

Louisiana-Specific Pharmacy and Regulatory Notes

Louisiana's Board of Pharmacy regulates both retail and compounding pharmacies in the state. For patients considering a compounded product, verifying that the pharmacy holds an active compounding license is a necessary step. The Board's online license verification tool allows patients to confirm a pharmacy's status by name or license number 4.

Louisiana does not impose additional state-level restrictions on bremelanotide beyond federal requirements. The drug is not a controlled substance. It does not require a state-specific prescribing protocol. Any physician, nurse practitioner, or physician assistant licensed in Louisiana with prescriptive authority can write the prescription.

Out-of-state compounding pharmacies shipping bremelanotide to Louisiana patients must be registered with the Louisiana Board of Pharmacy as non-resident pharmacies. Patients who order from out-of-state 503A pharmacies should confirm this registration to ensure legal compliance and recourse if a quality issue arises.